Intelligence » Lymphoma » Last Week

    Subscribe to get latest posts via email or subscribe to a RSS feed.

    EBRT Shows Promise in Relapsed/Refractory Follicular Lymphoma

    Saturday, March 17, 2018 -- External beam radiation therapy can be effective when integrated in a multimodality treatment strategy for patients with relapsed/refractory follicular lymphoma, according to findings from a small, retrospective study.

    Brentuximab Vedotin Approved by FDA for Hodgkin Lymphoma

    Wednesday, March 21, 2018 -- Based on findings from the phase III ECHELON-1 trial, brentuximab vedotin (Adcetris) has been approved by the FDA for use in combination with chemotherapy as a frontline treatment for adult patients with stage III or IV classical Hodgkin lymphoma, according to a statement from Seattle Genetics, the manufacturer of the CD30-targeted antibody-drug conjugate.

    Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

    Thursday, March 15, 2018 -- In this phase 1/2 study, brentuximab vedotin (BV) and nivolumab (Nivo) administered in combination were evaluated as initial salvage therapy in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (HL). Patients received up to 4 cycles of combination treatment, with BV administered on day 1 and Nivo on day 8 of the first cycle. For cycles 2 to 4, BV and Nivo were both administered on day 1. After study treatment, responses were evaluated by investigators per the 2014 Lugano classification, and patients could proceed to autologous stem cell transplantation (ASCT). Sixty-two patients were enrolled; the complete response rate among all treated patients (n = 61) was 61%, with an objective response rate of 82%. Before ASCT, adverse

    Adcetris + Chemo OK'd as Frontline Tx for Advanced Classical Hodgkin Lymphoma

    Tuesday, March 20, 2018 -- FDA approval was based on positive results from the Phase 3 ECHELON-1 trial.